Breaking Bottlenecks for the TCR Therapy of Cancer

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immune checkpoint inhibitors have advanced cancer treatment but rely on sufficient tumor-specific lymphocytes.
• Solid tumors often lack suitable antigens, limiting current immunotherapies.
• Cellular immunotherapies are rapidly evolving to overcome these limitations.

Purpose of the Study:

• To explore the potential of T-cell-receptor (TCR) engineered cell therapies for cancer treatment.
• To highlight advancements in identifying neoantigens and engineering T-cells for enhanced anti-tumor activity.
• To discuss the integration of next-generation features to combat tumor evasion and the immunosuppressive tumor microenvironment.

Main Methods:

• Utilizing next-generation sequencing and bioinformatic pipelines for rapid neoantigen identification (within 2 weeks).
• Employing high-throughput screening to select tumor-reactive TCRs.
• Implementing scalable non-viral gene editing for lymphocyte modification (autologous or allogeneic).
• Incorporating 'young' cell phenotypes (naive, stem, central memory) and 'next-generation' features to enhance T-cell persistence and function.

Main Results:

• TCR therapies enable targeting of multiple neoepitopes, crucial for preventing tumor immune evasion.
• Rapid identification and selection of tumor-reactive TCRs facilitate timely treatment.
• Gene editing allows for the creation of potent anti-cancer lymphocytes.
• 'Armored' T-cells demonstrate enhanced ability to overcome the immunosuppressive tumor microenvironment.

Conclusions:

• TCR engineered cell therapies represent a significant advancement in immuno-oncology.
• Technological breakthroughs in manufacturing and preclinical data support their potential.
• These therapies hold promise for treating heavily pretreated patients with previously intractable solid tumors, potentially heralding a new era in cancer treatment.